Articles tagged with Peptides
A cohort study investigates the association between bariatric surgery and preoperative use of GLP-1 receptor agonists. The results show a significant positive correlation between preoperative GLP-1 RA use and weight loss outcomes after surgery.
Rice engineers use electrical charge to control therapeutic peptide release from gelatin-based materials, enabling longer-lasting treatments. The study improves peptide retention and reduces initial burst release, offering potential for tailored release profiles in regenerative applications.
A study at USC discovers a common genetic variant in Indigenous American populations that silences the microprotein MENTSH, restoring it improves insulin signaling and blocks diet-induced weight gain. MENTSH-based therapies could offer a precision-medicine approach to Type 2 diabetes.
A study has shown that a peptide isolated from a Brazilian frog can increase the shelf life of strawberries by up to five days. The molecule preserves the fruit's firmness and chemical composition without affecting its flavor, offering a potential new approach to extend postharvest treatment.
Researchers developed an AI platform, PeptiVerse, to predict key properties of peptides, enabling early assessment of drug potential. The open-source platform allows users to evaluate ordinary and chemically modified peptides, streamlining the discovery process.
Researchers discover a previously unknown mechanism of action for a synthetic peptide that mitigates excessive inflammatory responses in allergic asthma. The peptide inhibits a key inflammatory switch in the immune system, opening up new avenues for treating chronic inflammatory diseases.
Researchers at the University of Pennsylvania and Chinese University of Hong Kong created TD3B, an AI framework guiding peptide generation toward candidates predicted to have a desired effect. The tool predicts binding likelihood and determines activation or deactivation of associated cellular machinery.
A secret shopper study found that online prescription vendors for GLP-1 receptor agonists often lack clinician interaction, relying on patient-reported questionnaires. This may lead to prescriptions being issued without important clinical and social history, compromising patient safety.
A cross-sectional study found significant increases in glucagon-like peptide-1 (GLP-1) per-patient days supplied in employer plans from 2021 to 2024, driven by higher growth in weight loss coverage. This could signal a growing financial burden on patients and payers as drug costs increase over time.
A recent study published in JAMA Otolaryngology–Head & Neck Surgery reveals a higher incidence of smell and taste disturbances among GLP-1 RA users. The findings underscore the importance of regular monitoring and awareness to mitigate these adverse effects.
A new chemical tagging approach has been developed to accurately sequence short peptides without relying on databases, opening possibilities for food science, nutrition, and biomedical research. The method successfully identified all 132 peptides with zero errors, highlighting its accuracy and reliability.
Researchers at Institute of Science Tokyo have developed a novel culture system to produce stable, scalable, and low-cost clinical-grade intestinal organoids from patient biopsy samples. The innovative approach uses clinical-grade collagen and synthetic peptides to enhance growth and improve scalability.
A team of scientists found that periods of darkness allow molecular assemblies to reorganize and evolve towards more stable structures. This process is faster and more effective than keeping the light on continuously.
A study found that adding orfglipron to titrated insulin glargine significantly improved glycemic control and body weight in participants with type 2 diabetes. The treatment did not increase the risk of hypoglycemia, compared to placebo.
Mazdutide, a GLP-1 receptor dual agonist, provides clinically meaningful weight reduction in Chinese adults with obesity. However, gastrointestinal adverse reactions are more common among those taking the drug compared to placebo.
Patients described GLP-1 RA therapy as a facilitator of lifestyle change, highlighting the need for standardized guidelines on patient education and clinical support. The quality of care was highly variable, leading to potential expectation management issues around adverse effects and long-term management.
Researchers at EPFL have discovered a way to generate and screen large libraries of synthetic cyclic peptides that can both enter cells and block disease-related protein interactions. This breakthrough could broaden access to previously difficult targets for drug development, enabling the creation of orally available peptide drugs.
A new study by the University of Ottawa suggests that a tiny molecule, methylglyoxal, plays a major role in triggering neurological disorders after a heart attack. The molecule accumulates in the brain following a heart attack and is linked to depression, anxiety, and cognitive decline.
Researchers have developed engineered peptide binders called CRABs that can selectively interfere with calcium signaling pathways, potentially leading to more effective and safer immunotherapies. The study's findings offer new hope for treating disorders linked to excessive CRAC-channel activity.
Antimicrobial peptides influence amyloid fibrillization through three mechanisms: structural compatibility, directional seeding asymmetry, and surface-mediated catalysis. This review proposes a bidirectional pathogen-amyloid feedback loop, linking infection and neurodegeneration.
A study found a significant decrease in metabolic bariatric surgery utilization between 2022 and 2024, with a 34.1% drop, while glucagon-like peptide-1 (GLP-1) use increased by 140.4% during the same period. This trend may continue due to growing prescribing of GLP-1s.
Researchers have developed a drug carrier that physically anchors itself to cancer cell membranes, improving drug retention and effectiveness. The technology maximizes tumor delivery of drugs while sparing normal tissues, resulting in safer and more effective therapies.
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
Researchers at USF Health developed a framework to test AI tools' accuracy in predicting immune responses, aiming to enhance cancer immunotherapies and vaccine development. The study highlights the strengths and weaknesses of current AI approaches, providing guidance for building safe and reliable AI tools for healthcare.
Researchers at UIC developed an anti-cancer therapy using a bacterial protein called aurB, which prevents energy production in tumor cells' mitochondria. The treatment was tested in combination with radiation and showed highly effective results in animal models of prostate cancer, effectively shutting down tumor growth.
A new clinical trial at the University of Cincinnati is testing a peptide solution to treat prosthetic joint infections after total knee replacement. The trial aims to reduce the need for repeat surgeries and expand the treatment window beyond two weeks.
A meta-analysis of GLP-1 receptor agonist studies found potential safety signals for gastrointestinal side effects, while some evidence suggested a link to reduced respiratory disease risk. Further research is needed to confirm the latter association.
Researchers from Kobe University have designed a small mirror protein that disables amyloid-beta, a causal factor of Alzheimer's disease. The approach uses the principle of 'chirality' to bind to the protein, inhibiting its aggregation and potential for brain cell damage.
A post hoc analysis of the Finerenone Trial reveals that sudden death in heart failure was often preceded by modest worsening of symptoms and declining quality of life. The study suggests limited specificity for sudden death among other modes of death, implying a complex trajectory before modes of death.
A post hoc analysis found that tirzepatide was associated with a lower incidence of a broad composite cardiovascular and kidney endpoint. The study compared tirzepatide with dulaglutide in patients with diabetes and established cardiovascular disease.
Continuing GLP-1/GIP agonists before upper endoscopy increased clinically significant residual gastric volume, but did not elevate adverse event risk. Clear liquids the day prior to the procedure may mitigate this risk.
Patients with type 2 diabetes and brain metastases who used GLP-1 receptor agonists showed a significant reduction in all-cause mortality. The use of these medications was associated with reduced neuroinflammation, preservation of the blood-brain barrier, and lowered oxidative stress and mitochondrial dysfunction.
A large cohort study found that fewer than 1 in 4 adults with overweight or obesity without diabetes remained on GLP-1RA treatment after 12 months. Treatment switching between GLP-1RA agents was common, reflecting active therapy management and the emergence of new formulations and weight management agents.
A low-cost digital intervention increased expectation to adopt health behaviors among adults using GLP-1RAs, with effects persisting for 2 weeks. The written microsteps intervention plus short video boosters may play a role in promoting sustained behavior change.
A novel plant-based approach uses lettuce chloroplasts to produce functional GLP-1 peptides, paving the way for more affordable and better-tolerated oral medications. This method bypasses hurdles such as manufacturing cost, delivery system, and side effects associated with conventional approaches.
A systematic review and meta-analysis found GLP-1 RAs produce significant weight loss across various subpopulations, including women who show improved outcomes compared to men. These findings have implications for clinical decision-making.
Researchers developed a novel method to immobilize proteins onto magnetic microbeads, allowing precise measurement of binding strength and efficient selection of target peptides. The technique achieved a 10,000-fold concentration in a single sorting step, significantly enhancing the efficiency of drug discovery research.
A team of scientists at the University of Sydney has discovered how three naturally occurring antibiotic compounds disrupt the ClpC1–ClpP1P2 complex, a vital protein degradation machine in Mycobacterium tuberculosis. This finding uncovers surprising complexity and provides valuable insight into designing more effective anti-TB treatments.
Researchers discovered that levetiracetam prevents the production of toxic amyloid-beta 42 peptides and plaques in neurons. Administering the drug to high-risk individuals may slow cognitive decline and prevent Alzheimer's symptoms if started early, possibly up to 20 years before symptoms appear.
A cohort study found combined GLP-1RA and progestin therapy reduces endometrial cancer risk in women with benign uterine pathology or endometrial hyperplasia. The study suggests potential benefits of this treatment approach for nonmalignant uterine diseases.
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly lowers risks of limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared to dipeptidyl peptidase-4 inhibitors in patients with diabetes. GLP-1 RAs are preferred for secondary prevention in this high-risk population.
After initiating GLP-1 receptor agonists, consumers showed a decrease in ultraprocessed foods and an increase in protein, while purchasing fewer calories, sugars, and saturated fats. These modest changes may have significant population-level effects given increasing GLP-1RA use.
A research team at Kumamoto University has developed a breakthrough drug-delivery platform using a small-intestine-permeable cyclic peptide, enabling efficient oral delivery of insulin. This approach achieves a pharmacological bioavailability of approximately 33–41% relative to subcutaneous injection.
A comparative effectiveness study found that SGLT2 inhibitors were associated with a lower risk of chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists. These findings suggest that SGLT2 inhibitor treatment may be an effective strategy for preventing kidney disease in individuals with type 2 diabetes.
Researchers at Cold Spring Harbor Laboratory have developed a new technique to improve mass spectrometry, enabling better drug target discovery and tumor analysis. The innovation increases sensitivity by breaking down scans into smaller bins, allowing for more accurate measurement of differences in concentration.
Using GLP-1 receptor agonists may lower the risk of vertebral compression fractures and related surgical interventions in people with type 2 diabetes. The study suggests that these medications have a bone-protective effect, offering benefits for patients.
A randomized clinical trial shows that semaglutide improves glycemic control and weight outcomes in individuals with schizophrenia. The study suggests using glucagon-like peptide-1 receptor agonists as an early intervention strategy to reduce cardiometabolic risk in this population.
Withdrawal of tirzepatide after 36-week treatment led to 25% or greater weight regain in most participants within a year, reversing initial cardiometabolic parameter improvements. Continued obesity treatment is crucial for sustained benefits.
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
A study found that women with obesity who stopped using GLP-1 receptor agonists experienced more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders. The research suggests that discontinuation of these medications may impact pregnancy outcomes.
A team of researchers from IOCB Prague introduces a novel method for labeling molecules with fluorescent dyes, surpassing existing approaches in precision and stability. This enables scientists to track labeled molecules over long periods with high reliability, expanding possibilities for research in biology, chemistry, and medicine.
Researchers identified two antimicrobial peptides that can kill various types of Salmonella and reduce its load in chickens. The study's findings suggest these peptides could improve food safety and public health by mitigating antibiotic resistance.
A cohort study found that GLP-1 receptor agonist use was associated with a reduced risk of developing nonexudative AMD, but not progression to exudative AMD in individuals with nonexudative AMD. This study may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
Researchers have discovered an enzyme called PapB that can create tight rings in therapeutic peptides, enabling the creation of stronger, longer-lasting versions of GLP-1 medications. This enzymatic method offers a simpler alternative to traditional chemical methods and could improve the stability and effectiveness of these drugs.
A new large language model, LassoESM, has been developed to predict lasso peptide properties, enabling the acceleration of rational design for biomedical applications. The model was trained on thousands of lasso peptide sequences and demonstrated accurate prediction of various properties.
A cohort study found that 40% of GLP-1RA orders were not filled, with lower rates among Non-Hispanic Black and Hispanic patients. These disparities may be attributed to differences in insurance coverage, GLP-1RA use, or cost thresholds.
The study reveals why some peptides are more effective and why certain bacterial cells are more vulnerable to membrane disruption. The findings provide a mathematical equation to identify optimal properties for efficacy, opening the door to designing novel compounds against antibiotic-resistant bacteria.
A new study from the Hebrew University of Jerusalem suggests that the stability of alpha amino acid backbones led to their selection as the foundation for proteins. The research proposes an assembly-driven model for the origins of life, offering fresh insight into how chemistry shaped biology.
Prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal, leading to substantial out-of-pocket costs. Out-of-pocket costs for GLP-1RAs rose significantly from 2020 to 2025, affecting many high-cost drugs.
A binational study found nearly 6 in 10 US adults and 3 in 10 Japanese adults discontinued semaglutide within 12 months of treatment. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates, highlighting the need for alternative treatments.